, Volume 17, Issue 3, pp 119–121 | Cite as

Bisphosphonates and Chronic Kidney Disease



  1. 1.
    Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk Factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis 2008;51:38–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Hruska KA, Teitelbaum SL. Mechanisms of disease: Renal osteodystrophy. N Eng J Med 1995;333:166–75.CrossRefGoogle Scholar
  6. 6.
    Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L, Bone Turnover Work Group. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004;43:558–65.PubMedCrossRefGoogle Scholar
  7. 7.
    World Health Organization. Assessment of fracture risk and its complication to screening for postmenopausal osteoporosis. Switzerland: Geneva; 1994.Google Scholar
  8. 8.
    Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J, Osteoporosis Work Group. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004;43:566–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(Suppl 2):S150–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80.PubMedCrossRefGoogle Scholar
  11. 11.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Park CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294–301.PubMedCrossRefGoogle Scholar
  12. 12.
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007;22:503–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Eng J Med 2007;356:1809–22.CrossRefGoogle Scholar
  15. 15.
    Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Eng J Med 2003;349:1676–9.CrossRefGoogle Scholar
  16. 16.
    Markowitz GS, Apple GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D’Agati VD. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephol 2001;12:1164–72.Google Scholar
  17. 17.
    Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD; HORIZON Pivotal Fracture Trial. Renal safety of annual zoledronic acid infusion in osteoporotic postmenopausal women. Kidney Int May 2008 Advance online publication.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Section of Nephrology (MC 793), Department of MedicineUniversity of Illinois Medical Center at ChicagoChicagoUSA
  2. 2.Section of Endocrinology, Department of MedicineUniversity of Illinois Medical Center at ChicagoChicagoUSA

Personalised recommendations